![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Percutaneous coronary intervention (PCI) has become the most important revascularization method in the treatment of coronary artery disease. The major problem in PCI has been renarrowing of the dilated vessel after the procedure (restenosis). The best results in the prevention of restenosis have been obtained by covering the stent with drugs that inhibit cellular growth, thus limiting excessive scar formation inside of the stent. With drug‐eluting stents, restenosis has been reduced to one‐tenth compared with balloon angioplasty and to one‐fourth compared to bare metal stents. Due to drug‐eluting stents, PCI is an alternative to bypass surgery. However, restenosis will remain a challenge due to the increased number of procedures and more difficult disease treated with PCI.
| Abbreviations | ||
| ACC/AHA | = | American College of Cardiology/American Heart Association |
| ACE | = | angiotensin‐converting enzyme |
| AT II | = | angiotensin II |
| bFGF | = | basic fibroblast growth factor |
| CABG | = | coronary artery bypass gratting |
| CRP | = | C‐reactive protein |
| EC | = | endothelial cell |
| IGF | = | insulin‐like growth factor |
| MAC‐1 | = | a member of beta2‐integrin family of cellular adhesion molecules |
| MACE | = | major adverse clinical event |
| MAPK | = | mitogen‐activated protein kinases |
| NO | = | nitric oxide |
| PCI | = | percutaneous coronary intervention |
| PDGF | = | platelet‐derived growth factor |
| QTc | = | corrected QT‐interval |
| SMC | = | smooth muscle cell |
| TGFβ | = | transforming growth factor beta |
| TLR | = | target lesion revascularization |
| TVR | = | target vessel revascularization |
| VEGF | = | vascular endothelial growth factor |
| Abbreviations | ||
| ACC/AHA | = | American College of Cardiology/American Heart Association |
| ACE | = | angiotensin‐converting enzyme |
| AT II | = | angiotensin II |
| bFGF | = | basic fibroblast growth factor |
| CABG | = | coronary artery bypass gratting |
| CRP | = | C‐reactive protein |
| EC | = | endothelial cell |
| IGF | = | insulin‐like growth factor |
| MAC‐1 | = | a member of beta2‐integrin family of cellular adhesion molecules |
| MACE | = | major adverse clinical event |
| MAPK | = | mitogen‐activated protein kinases |
| NO | = | nitric oxide |
| PCI | = | percutaneous coronary intervention |
| PDGF | = | platelet‐derived growth factor |
| QTc | = | corrected QT‐interval |
| SMC | = | smooth muscle cell |
| TGFβ | = | transforming growth factor beta |
| TLR | = | target lesion revascularization |
| TVR | = | target vessel revascularization |
| VEGF | = | vascular endothelial growth factor |